UK and Japan Launch £27M Science Partnership for Health

Britain and Japan are teaming up on a sweeping science partnership that could deliver life-changing treatments and revolutionary technology to millions of people.

The two countries just unveiled a joint initiative spanning life sciences, quantum research, and advanced connectivity. Together, they're investing more than £27 million in projects designed to accelerate breakthrough discoveries and bring them from the lab to real patients faster.

The biggest investment targets gene therapy for rare diseases. Japanese pharmaceutical company Kyowa Kirin plans to invest £11 million in the UK through its subsidiary Orchard Therapeutics, pending final government approval. That funding will support research into advanced gene therapies for severe genetic conditions that currently have few or no treatment options.

The UK already hosts more than 90 companies working on cell and gene therapies. This new investment strengthens that leadership position while creating high-skilled jobs and building on UK successes like life-saving treatments for rare childhood brain conditions.

A groundbreaking genomics partnership between Oxford Nanopore Technologies and Japanese genetic testing provider Genesis Healthcare will launch a national rare disease pilot in Japan starting in late 2026. The programme will use cutting-edge sequencing technology to screen for more than 70 underdiagnosed neuromuscular disorders through a single test, replacing multiple separate diagnostic procedures.

On the quantum front, three new research projects will bring together top scientists from both countries to tackle drug discovery, secure communications, and navigation systems. The UK's Engineering and Physical Sciences Research Council and Japan's Science and Technology Agency are jointly funding this work with nearly £10 million combined.

Both governments are also investing £6 million equally in advanced connectivity research. This programme will explore artificial intelligence in telecommunications, satellite networks, and high-capacity optical systems designed to deliver seamless mobile coverage and networks that can withstand cyber threats and natural disasters.

The Ripple Effect

These collaborations do more than advance science. They create lasting supply chains that support innovation in both countries, generating sustained demand for UK-manufactured research platforms while helping Japanese patients access genomic screening that could catch devastating diseases earlier.

The partnerships also train the next generation of researchers and clinicians, building expertise that will serve communities for decades. When scientists combine their strengths across borders, breakthroughs happen faster and reach more people who need them.

This UK-Japan alliance shows what's possible when nations choose cooperation over competition in science and technology.